WAKIX Significantly Reduced Excessive Daytime Sleepiness Versus Placebo in Adult Patients
Dr. Debra Stultz
Board-certified psychiatrist and sleep specialist
Dr. Debra Stultz
Board-certified psychiatrist and sleep specialist
STUDY 1: 35.6 mg once daily maximum potential dosage
Patient population
CI, confidence interval; ESS, Epworth Sleepiness Scale; LS, least squares.
*Primary endpoint: LS mean final ESS score compared with placebo. Final values shown as LS mean of the final 2 weeks (Week 7 and Week 8).1
†Placebo-subtracted difference (95% CI: -5.73, -0.46).
‡LS mean change from baseline to the final 2 weeks (Week 7 and Week 8); adjusted mean ESS score at baseline was 18.4.1
§Baseline values shown as raw mean values.
Study 1 design
Dr. Abhinav Singh
Board-certified internal medicine and sleep specialist
STUDY 3: 35.6 mg once daily maximum potential dosage
Patient population
CI, confidence interval.
*Primary endpoint: Final mean weekly rate of cataplexy over the 4-week stable dosing period compared with placebo (adjusted for baseline differences). Rate ratio 0.51 (95% CI: 0.44, 0.60); results were statistically significant.1
†Statistical comparison of geometric mean values was not conducted.
Study 3 design
References